Apitegromab BLA Moves to One Fill-Finish Facility
Scholar Rock will remove Catalent Indiana from the apitegromab biologics license application after FDA classified the site’s April inspection as Official Action Indicated. FDA review is proceeding with a second U.S. fill-finish facility, and…
